The value MOTS-C adds is in the quality of that weight loss experience better energy, improved exercise capacity, potential muscle preservation, and enhanced metabolic markers
Among the 18% of adults who report having ever used GLP-1 drugs, the vast majority (84%) say they have been diagnosed with at least one of the predominant conditions these drugs are prescribed to treat, including obesity or being overweight in the past five years (77%), or ever being diagnosed with diabetes (49%) or heart disease (21%)
Keep an eye on the retatrutide availability timeline for updates on these newer agents
Several major studies reported average body-weight reductions approaching 25-30%, placing Retatrutide among the most promising metabolic peptides currently under investigation
For most people there are few side effects
Comparison Summary Side-Effect Profile in Trials Reported side effects across all three compounds center on gastrointestinal events